106 related articles for article (PubMed ID: 22931268)
21. [Activated protein C in patients with septic shock: contra].
Graf J
Dtsch Med Wochenschr; 2010 Nov; 135(47):2371. PubMed ID: 21082531
[No Abstract] [Full Text] [Related]
22. Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?
Opal SM; LaRosa SP
Am J Respir Crit Care Med; 2013 May; 187(10):1041-3. PubMed ID: 23675711
[No Abstract] [Full Text] [Related]
23. The authors reply.
Rimmer E; Kumar A; Zarychanski R
Crit Care Med; 2013 Jul; 41(7):e139-40. PubMed ID: 23774364
[No Abstract] [Full Text] [Related]
24. Editors' comments on a new trial of activated protein C for persistent septic shock.
Mancebo J; Antonelli M
Intensive Care Med; 2008 Nov; 34(11):1948-9. PubMed ID: 18839138
[No Abstract] [Full Text] [Related]
25. Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome.
Barie PS; Hydo LJ; Shou J; Eachempati SR
Surg Infect (Larchmt); 2011 Dec; 12(6):443-9. PubMed ID: 22185191
[TBL] [Abstract][Full Text] [Related]
26. Recombinant human activated protein C for adults with septic shock: a randomized controlled trial.
Annane D; Timsit JF; Megarbane B; Martin C; Misset B; Mourvillier B; Siami S; Chagnon JL; Constantin JM; Petitpas F; Souweine B; Amathieu R; Forceville X; Charpentier C; Tesnière A; Chastre J; Bohe J; Colin G; Cariou A; Renault A; Brun-Buisson C; Bellissant E;
Am J Respir Crit Care Med; 2013 May; 187(10):1091-7. PubMed ID: 23525934
[TBL] [Abstract][Full Text] [Related]
27. A dream deferred: the rise and fall of recombinant activated protein C.
Holder AL; Huang DT
Crit Care; 2013 Mar; 17(2):309. PubMed ID: 23509922
[TBL] [Abstract][Full Text] [Related]
28. Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients.
Bilbault P; Lavaux T; Launoy A; Gaub MP; Meyer N; Oudet P; Pottecher T; Jaeger A; Schneider F
Crit Care Med; 2007 Jan; 35(1):69-75. PubMed ID: 17133181
[TBL] [Abstract][Full Text] [Related]
29. Who should fund CME?
Lexchin J
CJEM; 2013 May; 15(3):133. PubMed ID: 23663460
[No Abstract] [Full Text] [Related]
30. [Report of the 6th German Interdisciplinary Congress of Intensive and Emergency Medicine. Initial experiences with the new anti-infective drug drotrecogin alfa (activated) in septic shock].
Krankenpfl J; 2003; 41(1-3):27-9. PubMed ID: 12718261
[No Abstract] [Full Text] [Related]
31. Sepsis update: management of severe sepsis and septic shock in the emergency department after the withdrawal of Xigris.
Green RS; Djogovic D; Howes D
CJEM; 2012 Sep; 14(5):265-9. PubMed ID: 22967692
[No Abstract] [Full Text] [Related]
32. Resolving conflicting comparative effectiveness research in critical care*.
Seymour CW; Kahn JM
Crit Care Med; 2012 Nov; 40(11):3090-2. PubMed ID: 23080443
[No Abstract] [Full Text] [Related]
33. Reversal of refractory septic shock with drotrecogin alpha (activated).
Vieillard-Baron A; Caille V; Charron C; Belliard G; Aegerter P; Page B; Jardin F
Intensive Care Med; 2009 Jul; 35(7):1204-9. PubMed ID: 19529911
[TBL] [Abstract][Full Text] [Related]
34. [Endogenous anticoagulant therapy for sepsis. Success and failure].
Wiedermann CJ
Internist (Berl); 2007 May; 48(5):537-42, 544. PubMed ID: 17390117
[TBL] [Abstract][Full Text] [Related]
35. Human recombinant activated protein C for severe sepsis.
Martí-Carvajal AJ; Solà I; Lathyris D; Cardona AF
Cochrane Database Syst Rev; 2012 Mar; (3):CD004388. PubMed ID: 22419295
[TBL] [Abstract][Full Text] [Related]
36. Activated recombinant protein C in septic shock early after liver transplantation: a case report.
Feltracco P; Bortolato A; Rizzi S; Barbieri S; Furnari M; Serra E; Milevoj M; Ori C
Transplant Proc; 2008; 40(6):2070-2. PubMed ID: 18675133
[TBL] [Abstract][Full Text] [Related]
37. The use of recombinant human activated protein C (drotrecogin alpha) in solid organ transplant recipients: case series and review of the literature.
Funk DJ; Palma Vargas J; Tuttle-Newhall J; Moretti EW
Transpl Infect Dis; 2011 Dec; 13(6):592-7. PubMed ID: 21794040
[TBL] [Abstract][Full Text] [Related]
38. [Focal surgery, antibiotic therapy--and then? The role of rhAPC in sepsis].
Spies C; Otter H; Zuckermann-Becker H; Kox WJ
Kongressbd Dtsch Ges Chir Kongr; 2002; 119():834-43. PubMed ID: 12704933
[TBL] [Abstract][Full Text] [Related]
39. Biomarker response to drotrecogin alfa (activated) in children with severe sepsis: results from the RESOLVE clinical trial*.
Dalton HJ; Carcillo JA; Woodward DB; Short MA; Williams MD
Pediatr Crit Care Med; 2012 Nov; 13(6):639-45. PubMed ID: 22791090
[TBL] [Abstract][Full Text] [Related]
40. Drotrecogin alfa (activated) in severe sepsis.
LaRosa SP
N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395833
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
